Isabelle Cojean-Zelek
Overview
Explore the profile of Isabelle Cojean-Zelek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orlando V, Drubay D, Lavaud P, Faivre L, Lesaunier F, Delva R, et al.
Clin Genitourin Cancer
. 2023 Jun;
21(5):615.e1-615.e8.
PMID: 37263910
Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases...
2.
Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, et al.
Br J Cancer
. 2019 Mar;
120(7):697-702.
PMID: 30837681
Background: Ampullary adenocarcinoma (AA) originates from either intestinal (INT) or pancreaticobiliary (PB) epithelium. Different prognostic factors of recurrence have been identified in previous studies. Methods: In 91 AA patients of...
3.
Vicier C, Baciarello G, Arfi-Rouche J, Massard C, Loriot Y, Albiges L, et al.
Clin Genitourin Cancer
. 2019 Feb;
17(3):e485-e487.
PMID: 30792009
No abstract available.
4.
Bouaud J, Spano J, Lefranc J, Cojean-Zelek I, Blaszka-Jaulerry B, Zelek L, et al.
Stud Health Technol Inform
. 2015 Aug;
216:264-9.
PMID: 26262052
When wrongly used, guideline-based clinical decision support systems (CDSSs) may generate inappropriate propositions that do not match the recommendations provided by clinical practice guidelines (CPGs). The user may decide to...
5.
Chanat C, Delbaldo C, Denis J, Bocaccio F, Cojean-Zelek I, Guyader N
Anticancer Drugs
. 2015 Aug;
26(9):984-9.
PMID: 26237498
Docetaxel is an antineoplastic drug from the taxane family that inhibits tubulin polymerization. Its brand name is Taxotere. In mid-2010, the formulation of Taxotere changed from a two-vial preparation needing...
6.
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al.
Lancet Oncol
. 2015 Jun;
16(7):787-94.
PMID: 26028518
Background: Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and estramustine improves survival in patients with...
7.
Bouaud J, Blaszka-Jaulerry B, Zelek L, Spano J, Lefranc J, Cojean-Zelek I, et al.
AMIA Annu Symp Proc
. 2015 May;
2014:315-24.
PMID: 25954334
The potential of health information technology is hampered by new types of errors which impact is not totally assessed. OncoDoc2 is a decision support system designed to support treatment decisions...
8.
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, et al.
Ann Oncol
. 2015 Mar;
26(4):822-825.
PMID: 25814651
No abstract available.
9.
Seroussi B, Soulet A, Spano J, Lefranc J, Cojean-Zelek I, Blaszka-Jaulerry B, et al.
Stud Health Technol Inform
. 2013 Aug;
192:534-8.
PMID: 23920612
OncoDoc2 is a guideline-based clinical decision support system (CDSS) for breast cancer management. It has been used as an intervention in a randomized controlled trial carried out to evaluate the...
10.
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, et al.
Eur J Cancer
. 2011 Nov;
48(2):209-17.
PMID: 22119204
Aim: To assess docetaxel-estramustine in patients with localised high-risk prostate cancer. Patients And Methods: After staging pelvic lymph node dissection, patients with high-risk prostate cancer randomly received androgen deprivation therapy...